Chugai Presents Updated Results From Phase III ALEX Study Of Alecensa Vs Crizotinib In Untreated Advanced ALK+ NSCLC At ASCO Programme

Chugai Pharmaceutical announced that updated data from the global phase III study (the ALEX study) for Alecensa was presented the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program. The ALEX study compared Alecensa and crizotinib as the first-line therapy for patients with ALK fusion gene positive non-small cell lung cancer (NSCLC). Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC. Dr. Osamu Okuda, Chugai's president and COO, said "This five-year follow-up data from the ALEX study shows the long-term benefits of Alecensa as the first-line treatment of ALK-positive NSCLC. This reaffirms the position of Alecensa as one of the standard treatments." At the updated data cut-off point, median duration of follow-up was 48.2 months (range: 0.5 - 62.7) and 23.3 months (range: 0.3 - 60.6) in the Alecensa and crizotinib arms, respectively. The number of overall survival (OS) events was 37% of the ITT population, median OS in the crizotinib arm was 57.4 months (95%CI: 34.6 – not estimable) and not estimable in the Alecensa arm (HR=0.67, 95%CI: 0.46 - 0.98). The 5-year survival rate was 62.5% (95%CI: 54.3 - 70.8) and 45.5% (95%CI: 33.6 - 57.4) in the Alecensa and crizotinib arms, respectively (secondary endpoint). In patients with CNS metastases at baseline, the OS hazard ratio was 0.58 (95%CI: 0.34 - 1.00) and 0.76 (95%CI: 0.45 - 1.26) in patients without CNS metastases at baseline (secondary endpoint). No new safety signals were observed, and the safety profile of Alecensa was consistent with previous reports. The dosage and administration of the ALEX study is "600mg alectinib administered orally twice daily," which is different from the Japanese dosage and administration.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!